Yang, Tong
Zheng, Hongmei
Pan, Guangwei
Guo, Ruiying
Liu, Fengmin
Liu, Shengyuan
Tao, Shuang
Li, Lin
Yang, Rongrong
Yu, Chunquan
Clinical trials referenced in this document:
Documents that mention this clinical trial
Relationship between the circulating N-terminal pro B-type natriuretic peptide and the risk of carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a CSCD-TCM plus study in China
https://doi.org/10.1186/s12933-023-02015-y
Funding for this research was provided by:
National Natural Science Foundation of China (82074140)
Tianjin Hongrentang Pharmaceutical Co., Ltd., Tianjin, China (No.HX2020-16)
Shanghai Hutchison Pharmaceuticals Ltd. (No. HX2020-39)
Tianjin Health Commission and Tianjin Bureau of Traditional Chinese Medicine (2021057)
Article History
Received: 26 August 2023
Accepted: 7 October 2023
First Online: 2 November 2023
Declarations
:
: The study was approved by the Ethics Committee of Tianjin University of Traditional Chinese Medicine (approval number TJUTCM-EC20210007) and certified by the Chinese Clinical Trials Registry on April 4, 2022 (registration number ChiCTR2200058296) and on March 25, 2022 by ClinicalTrials.gov (registration number NCT05309343).
: Not applicable.
: The authors declare no competing interests.